Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsSTU:RGO -0.05%84 Buyback Yield % is 4.30 as of Jul. 20, 2026, which is 287% above its 10-year median of 1.11. GuruFocus rates STU:RGO with a GF Score™ of 84/100 and a GF Value™ of €785.48 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 740 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 98.38% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RGO vs ALNY, RVMD, ONC: Buyback Yield % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (STU:RGO) has a Buyback Yield % of 4.30 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Regeneron Pharmaceuticals and its competitors. This is 287% above median its historical median of 1.11. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #12 out of 740 companies in the Biotechnology industry, placing it in the top 1.6%.
Is Regeneron Pharmaceuticals' Buyback Yield % too high?
Regeneron Pharmaceuticals' current Buyback Yield % of 4.30 is 287% above median its 10-year median of 1.11. Based on the distribution chart, Regeneron Pharmaceuticals ranks #12 out of 740 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Buyback Yield % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #12 out of 740 companies for Buyback Yield %. This places Regeneron Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Buyback Yield % is 4.30, which is 287% above median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €785.48, compared to a current price of €592.00 — trading 24.6% below its estimated fair value. The current Buyback Yield % is 4.30, which is 287% above median its 10-year median of 1.11. Regeneron Pharmaceuticals' overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Buyback Yield % is 4.30 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €592.00 is trading 24.6% below its estimated GF Value™ of €785.48.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for STU:RGO:
Buyback Yield %: 4.30 (287% above median its 10-year median of 1.11)
GF Value™: €785.48 vs. price of €592.00 (24.6% below fair value)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
84GF Score
Get the complete analysis for STU:RGO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
